## Andrew R Reynolds

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10767810/publications.pdf Version: 2024-02-01



ANDREW R REVNOLDS

#	Article	IF	CITATIONS
1	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	27.6	792
2	Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis, 2014, 17, 471-494.	7.2	626
3	Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nature Medicine, 2009, 15, 392-400.	30.7	428
4	Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nature Medicine, 2016, 22, 1294-1302.	30.7	342
5	Quantitative Imaging of Lateral ErbB1 Receptor Signal Propagation in the Plasma Membrane. , 2000, 290, 1567-1570.		319
6	Vessel co-option in cancer. Nature Reviews Clinical Oncology, 2019, 16, 469-493.	27.6	285
7	EGFR activation coupled to inhibition of tyrosine phosphatases causes lateral signal propagation. Nature Cell Biology, 2003, 5, 447-453.	10.3	218
8	The Multifaceted Role of the Microenvironment in Liver Metastasis: Biology and Clinical Implications. Cancer Research, 2013, 73, 2031-2043.	0.9	177
9	International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. British Journal of Cancer, 2017, 117, 1427-1441.	6.4	172
10	Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. Journal of Pathology, 2017, 241, 362-374.	4.5	162
11	Elevated Flk1 (Vascular Endothelial Growth Factor Receptor 2) Signaling Mediates Enhanced Angiogenesis in β3-Integrin–Deficient Mice. Cancer Research, 2004, 64, 8643-8650.	0.9	148
12	Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2016, 108, djw030.	6.3	144
13	Integrins in angiogenesis: multitalented molecules in a balancing act. Cell and Tissue Research, 2003, 314, 131-144.	2.9	142
14	Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models. Cancer Research, 2016, 76, 787-795.	0.9	133
15	Non-angiogenic tumours and their influence on cancer biology. Nature Reviews Cancer, 2018, 18, 323-336.	28.4	113
16	Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer. Dose-Response, 2010, 8, dose-response.0.	1.6	95
17	αvβ3 Integrin Limits the Contribution of Neuropilin-1 to Vascular Endothelial Growth Factor-induced Angiogenesis. Journal of Biological Chemistry, 2009, 284, 33966-33981.	3.4	88
18	The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. European Journal of Cancer, 2017, 75, 245-258.	2.8	82

ANDREW R REYNOLDS

#	Article	IF	CITATIONS
19	Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis, 2020, 23, 55-74.	7.2	77
20	Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis, 2012, 15, 623-641.	7.2	74
21	The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer. Clinical Cancer Research, 2013, 19, 6924-6934.	7.0	62
22	Essential Role for Endocytosis in the Growth Factor-stimulated Activation of ERK1/2 in Endothelial Cells. Journal of Biological Chemistry, 2013, 288, 7467-7480.	3.4	60
23	The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis. Current Biology, 2016, 26, 755-765.	3.9	57
24	Endothelial α3β1-Integrin Represses Pathological Angiogenesis and Sustains Endothelial-VEGF. American Journal of Pathology, 2010, 177, 1534-1548.	3.8	54
25	Mechanism of tumour vascularization in experimental lung metastases. Journal of Pathology, 2015, 235, 384-396.	4.5	53
26	Apatinib for the treatment of gastric cancer. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1-6.	3.0	51
27	Nanoparticle-mediated gene delivery to tumour neovasculature. Trends in Molecular Medicine, 2003, 9, 2-4.	6.7	47
28	Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. Molecular Cancer Therapeutics, 2016, 15, 172-183.	4.1	35
29	Mapping Hypoxia in Renal Carcinoma with Oxygen-enhanced MRI: Comparison with Intrinsic Susceptibility MRI and Pathology. Radiology, 2018, 288, 739-747.	7.3	34
30	Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. British Journal of Cancer, 2022, 127, 988-1013.	6.4	30
31	Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma <i>In Vivo</i> with Susceptibility Contrast MRI. Cancer Research, 2017, 77, 4127-4134.	0.9	26
32	Runt related transcription factor-1 plays a central role in vessel co-option of colorectal cancer liver metastases. Communications Biology, 2021, 4, 950.	4.4	26
33	Farnesyltransferase inhibitors target multiple endothelial cell functions in angiogenesis. Angiogenesis, 2008, 11, 337-346.	7.2	11
34	The evidence for and against different modes of tumour cell extravasation in the lung: diapedesis, capillary destruction, necroptosis, and endothelialization. Journal of Pathology, 2017, 241, 441-447.	4.5	8
35	Reply to: "Will integrin inhibitors have proangiogenic effects in the clinic?― Nature Medicine, 2009, 15, 727-727.	30.7	6
36	Tumor Stromal Phenotypes Define VEGF Sensitivity—Letter. Clinical Cancer Research, 2014, 20, 5140-5140.	7.0	4

#	Article	IF	CITATIONS
37	Bevacizumab beyond progression in breast cancer. Lancet Oncology, The, 2014, 15, 1190-1191.	10.7	2
38	Lessons from the first ecancer symposium on angiogenesis in gastric cancer. Ecancermedicalscience, 2015, 9, 553.	1.1	0